Infection and Drug Resistance (Jun 2024)

Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-Positive Klebsiella pneumoniae MBL+, NDM+

  • Szymański M,
  • Skiba MM,
  • Piasecka M,
  • Olender A

Journal volume & issue
Vol. Volume 17
pp. 2307 – 2313

Abstract

Read online

Mateusz Szymański,1,2 Małgorzata M Skiba,2 Małgorzata Piasecka,2 Alina Olender3 1Human Anatomy Department, Medical University, Lublin, Poland; 2Intensive Care Unit, Stefan Cardinal Wyszyński District Specialist Hospital, Lublin, Poland; 3Chair and Department of Medical Microbiology, Medical University, Lublin, PolandCorrespondence: Małgorzata M Skiba, Intensive Care Unit, Stefan Cardinal Wyszyński District Specialist Hospital, Al. Kraśnicka 100, Lublin, 20-718, Poland, Tel +48 81 537 46 60, Email [email protected]: The difficulties in attaining effective antibiotic therapy arising from the multidrug resistance of Gram-negative bacilli compel the exploration of new possibilities for synergistic interactions among existing antibiotics.Research Design and Methods: An analysis was conducted to assess the efficacy of two antibiotic therapy regimens in the treatment of infections caused by Klebsiella pneumoniae strains producing carbapenemases (MBL). Two patient groups were considered: Group A – individuals in whom the treatment of infection involved the application of ceftazidime-avibactam in combination with aztreonam. Group B comprised patients subjected to an alternative antibiotic therapy regimen.Results: In the group subjected to the treatment regimen involving ceftazidime-avibactam and aztreonam, as compared to alternative antibiotic combinations, a statistically lower mortality rate during the course of treatment and a faster clinical response to the administered therapy were evident.Conclusion: The results obtained may be applicable to routine in vitro assays performed and serve as valuable guidance for the potential utilization of the positive effect of antibiotic therapy through the synergy between ceftazidime-avibactam and aztreonam. The selection of antibiotics employed in the therapy of invasive infections caused by K. pneumoniae influences the ultimate treatment outcome.Keywords: synergism, ceftazidime-avibactam, aztreonam, multidrug-resistant K. pneumoniae, metal-beta-lactamases

Keywords